Group 1 - The chairman of Charoen Pokphand International (03839.HK), Mr. Xie Jiren, has been appointed as an executive director effective from February 24, 2026, due to his new executive role within the group [1] - Mr. Li Shaozhu has resigned as the executive director and CEO (Industrial Business) to focus on personal matters, and he will no longer serve as a member of the board's remuneration committee [1] - Ms. Kobboon Srichai has been appointed as a non-executive director of the company [1] Group 2 - Mr. Ma Deshou has been appointed as the CEO and a member of the remuneration committee following his appointment as an executive director [1] - Mr. Li Shaoqing will remain as an executive director but will no longer serve as the CEO (Biochemical Business) after Mr. Ma's appointment [1] - As of the market close on February 24, 2026, Charoen Pokphand International (03839.HK) was trading at HKD 6.68, down 0.15%, with a trading volume of 128,000 shares and a turnover of HKD 856,200 [1] Group 3 - Charoen Pokphand International has a market capitalization of HKD 1.61 billion and ranks 37th in the biopharmaceutical II industry [1] - There has been low attention from investment banks regarding this stock, with no ratings provided in the last 90 days [1]
正大企业国际(03839.HK)委任Kobboon Srichai 为非执行董事